
  
    
      
        
        Only_RB about_IN 1_CD %_NN of_IN newly_RB developed_VBN drugs_NNS are_VBP for_IN tropical_JJ diseases_NNS ,_, such_JJ as_IN African_JJ
        sleeping_NN sickness_NN ,_, dengue_NN fever_NN ,_, and_CC leishmaniasis_NNS [_NN 1_CD ]_NN ._. While_IN patent_NN incentives_NNS and_CC
        commercial_JJ pharmaceutical_JJ houses_NNS have_VBP made_VBN Western_JJ health_NN care_NN the_DT envy_NN of_IN the_DT world_NN ,_, the_DT
        commercial_JJ model_NN only_RB works_VBZ if_IN companies_NNS can_MD sell_VB enough_RB patented_VBD products_NNS to_TO cover_VB their_PRP$
        research_NN and_CC development_NN (_( R_NN &_CC D_NNP )_) costs_NNS ._. The_DT model_NN fails_VBZ in_IN the_DT developing_VBG world_NN ,_, where_WRB
        few_JJ patients_NNS can_MD afford_VB to_TO pay_VB patented_VBD prices_NNS for_IN drugs_NNS ._.
        It_PRP is_VBZ easy_JJ and_CC correct_JJ to_TO say_VB that_IN Western_JJ governments_NNS could_MD solve_VB this_DT problem_NN by_IN
        paying_VBG existing_VBG institutions_NNS to_TO focus_VB on_IN cures_NNS for_IN tropical_JJ diseases_NNS ._. But_CC sadly_RB ,_, there_EX does_VBZ
        not_RB appear_VB to_TO be_VB enough_RB political_JJ will_MD for_IN this_DT to_TO happen_VB ._. In_IN any_DT case_NN ,_, grants_NNS and_CC patent_NN
        incentives_NNS were_VBD never_RB designed_VBN with_IN tropical_JJ diseases_NNS in_IN mind_NN ._.
        Two_CD main_JJ kinds_NNS of_IN proposals_NNS have_VBP been_VBN suggested_VBN for_IN tackling_VBG the_DT problem_NN ._. The_DT first_JJ is_VBZ
        to_TO ask_VB sponsors—governments_NNS and_CC charities—to_NN subsidize_VB developing-country_JJ purchases_NNS at_IN a_DT
        guaranteed_VBN price_NN [_NN 2_CD ,_, 3_CD ,_, 4_CD ]_NN ._. The_DT second_JJ involves_VBZ charities_NNS creating_VBG nonprofit_JJ venture-capital_JJ
        firms_NNS (_(“ Virtual_NNP Pharmas_NNP” )_) ,_, which_WDT look_VBP for_IN promising_JJ drug_NN candidates_NNS and_CC then_RB push_VB drug_NN
        development_NN through_IN contracts_NNS with_IN corporate_JJ partners_NNS ._. In_IN this_DT article_NN ,_, we_PRP discuss_VBP the_DT
        limitations_NNS of_IN these_DT two_CD approaches_NNS and_CC suggest_VBP a_DT third_JJ ,_, “ open_JJ source_NN ,_,” approach_NN to_TO drug_NN
        development_NN ,_, called_VBD the_DT Tropical_NNP Diseases_NNP Initiative_NNP (_( TDI_NNP )_) ._. We_PRP envisage_NN TDI_NNP as_IN a_DT
        decentralized_JJ ,_, Web-based_NNP ,_, community-wide_JJ effort_NN where_WRB scientists_NNS from_IN laboratories_NNS ,_,
        universities_NNS ,_, institutes_NN ,_, and_CC corporations_NNS could_MD work_VB together_RB for_IN a_DT common_JJ cause_NN (_( see_VB
        www_NN ._. tropicaldisease_NN ._. org_NN )_) ._.
      
      
        Why_WRB Open_NNP Source_NNP ?_.
        The_DT idea_NN behind_IN asking_VBG sponsors_NNS to_TO subsidize_VB developing_VBG country_NN purchases_NNS at_IN a_DT
        guaranteed_VBN price_NN is_VBZ that_IN this_DT will_MD prop_VB up_RP drug_NN prices_NNS and_CC restore_VB incentives_NNS for_IN
        developing_VBG new_JJ drugs_NNS [_NN 2_CD ,_, 3_CD ,_, 4_CD ]_NN ._. In_IN other_JJ words_NNS ,_, it_PRP is_VBZ a_DT way_NN of_IN fixing_VBG the_DT patent_NN problem_NN ._.
        However_RB ,_, subsidies_NNS have_VBP an_DT important_JJ weakness_NN :_: it_PRP is_VBZ almost_RB impossible_JJ to_TO determine_VB
        correctly_RB how_WRB large_JJ the_DT subsidy_NN should_MD be_VB ._. In_IN principle_NN ,_, the_DT most_RBS cost-effective_JJ solution_NN
        is_VBZ to_TO set_VB a_DT subsidy_NN that_WDT just_RB covers_VBZ expected_VBN R_NN &_CC D_NNP costs_NNS ._. But_CC how_WRB large_JJ is_VBZ that_DT ?_. R_NN &_CC D_NNP
        costs_NNS are_VBP very_RB poorly_RB known_VBN ,_, with_IN the_DT published_VBN estimates_NNS quoting_VBG uncertainties_NNS exceeding_VBG
        $_$ 100_CD to_TO $_$ 500_CD million_CD per_IN drug_NN ._. If_IN the_DT subsidy_NN is_VBZ set_VBN too_RB low_JJ ,_, companies_NNS cannot_NN cover_NN their_PRP$
        R_NN &_CC D_NNP costs_NNS and_CC nothing_NN will_MD happen_VB ._. Set_NNP the_DT subsidy_NN too_RB high_JJ ,_, and_CC the_DT sponsor_NN 's_POS costs_NNS
        skyrocket_NN ._. To_TO date_NN ,_, no_DT sponsor_NN has_VBZ tried_VBN to_TO implement_VB these_DT proposals_NNS ._.
        In_IN the_DT “ Virtual_NNP Pharma_NNP” approach_NN ,_, governments_NNS and_CC philanthropies_NNS fund_VBP organizations_NNS that_WDT
        identify_VBP and_CC help_VB support_VB the_DT most_RBS promising_JJ private_JJ and_CC academic_JJ research_NN ._. Examples_NNS
        include_VBP the_DT Institute_NNP for_IN One_CD World_NNP Health_NNP (_( www_NN ._. iowh_NN ._. org_NN )_) ,_, a_DT not-for-profit_JJ pharmaceutical_JJ
        company_NN funded_VBN mainly_RB through_IN private_JJ sources_NNS and_CC the_DT Gates_NNP Foundation_NNP ,_, and_CC the_DT Drugs_NNS for_IN
        Neglected_NNP Diseases_NNP Initiative_NNP (_( www_NN ._. dndi_NN ._. org_NN )_) ,_, a_DT public_JJ sector_NN not-for-profit_JJ organization_NN
        designed_VBN to_TO mobilize_VB resources_NNS for_IN R_NN &_CC D_NNP on_IN new_JJ drugs_NNS for_IN neglected_VBN diseases_NNS ._.
        Virtual_NNP Pharmas_NNP have_VBP clearly_RB started_VBN to_TO bear_VB fruit_NN ,_, and_CC are_VBP responsible_JJ for_IN most_JJS
        candidate_NN treatments_NNS for_IN tropical_JJ diseases_NNS currently_RB under_IN development_NN ._. For_IN example_NN ,_, the_DT
        Drugs_NNS for_IN Neglected_NNP Diseases_NNP Initiative_NNP has_VBZ a_DT portfolio_NN of_IN nine_CD projects_NNS spread_VBP out_IN across_IN
        the_DT drug_NN development_NN pipeline_NN for_IN the_DT treatment_NN of_IN leishmaniasis_NNS ,_, sleeping_VBG sickness_NN ,_, Chagas_NNP
        disease_NN ,_, and_CC malaria_NN [_NN 6_CD ]_NN ._. But_CC Virtual_NNP Pharmas_NNP face_NN three_CD important_JJ problems_NNS ._. The_DT first_JJ is_VBZ
        similar_JJ to_TO the_DT problem_NN faced_VBN by_IN subsidy_NN proposals_NNS :_: guessing_VBG private-sector_JJ R_NN &_CC D_NNP costs_NNS ._.
        One_CD needs_VBZ to_TO understand_VB what_WP a_DT product_NN costs_NNS in_IN order_NN to_TO negotiate_VB the_DT best_JJS possible_JJ
        price—and_NN guessing_VBG wrong_NN is_VBZ likely_JJ to_TO be_VB expensive_JJ ._. Second_JJ ,_, Virtual_NNP Pharma_NNP 's_POS development_NN
        pipelines_NNS will_MD run_VB dry_JJ without_IN more_RBR upstream_RB research_NN ._. Research_NNP has_VBZ been_VBN particularly_RB weak_JJ
        in_IN exploiting_VBG genomic_JJ insights_NNS [_NN 7_CD ]_NN ._. Third_NNP ,_, tropical_JJ disease_NN research_NN is_VBZ badly_RB underfunded_VBN ._.
        For_IN this_DT reason_NN ,_, Virtual_NNP Pharma_NNP cannot_NN succeed_VB without_IN rigid_JJ cost_NN containment_NN ._.
        We_PRP believe_VBP that_IN a_DT new_JJ ,_, community-wide_JJ consortium_NN ,_, the_DT Tropical_NNP Disease_NNP Initiative_NNP ,_, can_MD
        help_VB solve_VB these_DT problems_NNS ._. Its_PRP$ success_NN would_MD help_VB keep_VB Virtual_NNP Pharma_NNP 's_POS R_NN &_CC D_NNP pipeline_NN
        full_JJ ._. Furthermore_RB ,_, it_PRP would_MD use_VB open-source_JJ licenses_NNS to_TO keep_VB its_PRP$ discoveries_NNS freely_RB
        available_JJ to_TO researchers_NNS and—eventually—manufacturers_NNS ._. As_IN we_PRP explain_VBP below_RB ,_, well-designed_JJ
        open-source_JJ licenses_NNS are_VBP the_DT key_NN to_TO containing_VBG Virtual_NNP Pharmas_NNP '_POS R_NN &_CC D_NNP costs_NNS ._.
        While_IN we_PRP expect_VBP the_DT final_JJ choice_NN of_IN license_NN to_TO be_VB made_VBN by_IN TDI_NNP 's_POS members_NNS ,_, the_DT guiding_VBG
        principle_NN should_MD be_VB to_TO pick_VB whatever_WDT license_VBP lets_VBZ developing_VBG country_NN patients_NNS derive_VB the_DT
        most_JJS benefit_NN from_IN TDI_NNP 's_POS work_NN ._. Possible_JJ choices_NNS are_VBP shown_VBN in_IN Box_NNP 1_CD ._.
      
      
        How_WRB It_PRP Works_NNP
        To_TO date_NN ,_, open-source_JJ methods_NNS have_VBP made_VBN little_JJ headway_NN beyond_IN software_NN [_NN 8_CD ]_NN ._. However_RB ,_,
        computing_NN and_CC computational_NN biology_NN are_VBP converging_VBG ._. In_IN the_DT same_JJ way_NN that_IN programmers_NNS find_VBP
        bugs_NNS and_CC write_VB patches_NNS ,_, biologists_NNS look_VBP for_IN proteins_NNS (_(“ targets_NNS” )_) and_CC select_VB chemicals_NNS
        (_(“ drug_NN candidates_NNS” )_) that_DT bind_NN to_TO them_PRP and_CC affect_VB their_PRP$ behavior_NN in_IN desirable_JJ ways_NNS ._. In_IN both_DT
        cases_NNS ,_, research_NN consists_VBZ of_IN finding_VBG and_CC fixing_VBG tiny_JJ problems_NNS hidden_VBN in_IN an_DT ocean_NN of_IN
        code_NN ._.
        What_WP would_MD open-source_JJ drug_NN discovery_NN look_NN like_IN ?_. As_IN with_IN current_JJ software_NN
        collaborations_NNS ,_, we_PRP propose_VBP a_DT Web_NNP site_NN where_WRB volunteers_NNS use_VBP a_DT variety_NN of_IN computer_NN programs_NNS ,_,
        databases_NNS ,_, and_CC computing_NN hardware_NN (_( Figure_NN 1_LS )_) ._. Individual_JJ pages_NNS would_MD host_VB tasks_NNS like_IN
        searching_VBG for_IN new_JJ protein_NN targets_NNS ,_, finding_VBG chemicals_NNS to_TO attack_VB known_VBN targets_NNS ,_, and_CC posting_VBG
        data_NNS from_IN related_VBN chemistry_NN and_CC biology_NN experiments_NNS ._. Volunteers_NNP could_MD use_VB chat_VB rooms_NNS and_CC
        bulletin_NN boards_NNS to_TO announce_VB discoveries_NNS and_CC debate_VB future_JJ research_NN directions_NNS ._. Over_IN time_NN ,_,
        the_DT most_RBS dedicated_VBN and_CC proficient_JJ volunteers_NNS would_MD become_VB leaders_NNS ._.
        Ten_CD years_NNS ago_RB ,_, TDI_NNP would_MD not_RB have_VB been_VBN feasible_JJ ._. The_DT difference_NN today_NN is_VBZ the_DT vastly_RB
        greater_JJR size_NN and_CC variety_NN of_IN chemical_NN ,_, biological_JJ ,_, and_CC medical_JJ databases_NNS ;_: new_JJ software_NN ;_: and_CC
        more_RBR powerful_JJ computers_NNS ._. Researchers_NNS can_MD now_RB identify_VB promising_JJ protein_NN targets_NNS and_CC small_JJ
        sets_NNS of_IN chemicals_NNS ,_, including_VBG good_JJ lead_NN compounds_NNS ,_, using_VBG computation_NN alone_RB ._. For_IN example_NN ,_, a_DT
        SARS_NNP protein_NN similar_JJ to_TO mRNA_NN cap-_NN 1_CD methyltransferases—a_NN class_NN of_IN proteins_NNS with_IN available_JJ
        inhibitors—was_NNS recently_RB identified_VBN by_IN scanning_VBG proteins_NNS encoded_JJ by_IN the_DT SARS_NNP genome_NN against_IN
        proteins_NNS of_IN known_VBN structure_NN [_NN 9_CD ]_NN ._. This_DT discovery_NN provides_VBZ an_DT important_JJ new_JJ target_NN for_IN future_JJ
        experimental_JJ validation_NN and_CC iterative_JJ lead_NN optimization_NN ._. More_RBR generally_RB ,_, existing_VBG projects_NNS
        such_JJ as_IN the_DT University_NNP of_IN California_NNP at_IN San_NNP Francisco_NNP 's_POS Tropical_NNP Disease_NNP Research_NNP Unit_NNP (_( San_NNP
        Francisco_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) show_NN that_IN even_RB relatively_RB modest_JJ computing_NN ,_,
        chemistry_NN ,_, and_CC biology_NN resources_NNS can_MD deliver_VB compounds_NNS suitable_JJ for_IN clinical_JJ trials_NNS [_NN 10_CD ]_NN ._.
        Increases_NNS in_IN computing_NN power_NN and_CC improved_VBN computational_NN tools_NNS will_MD make_VB these_DT methods_NNS even_RB
        more_RBR powerful_JJ in_IN the_DT future_NN ._.
        Just_RB as_IN they_PRP do_VBP today_NN ,_, Virtual_NNP Pharmas_NNP would_MD choose_VB the_DT best_JJS candidates_NNS ._. The_DT difference_NN
        is_VBZ that_IN open-source_JJ drugs_NNS could_MD not_RB be_VB patented_VBN in_IN developing_VBG countries_NNS ._. This_DT would_MD not_RB
        stop_VB Virtual_NNP Pharma_NNP from_IN developing_VBG promising_JJ discoveries_NNS ._. (_( S_NNP ._. Nwaka_NNP ,_, V_NNP ._. Hale_NNP ,_, personal_JJ
        communications_NNS )_) ._. Importantly_NNP ,_, TDI_NNP would_MD be_VB a_DT great_JJ boost_NN to_TO the_DT efforts_NNS of_IN Virtual_NNP Pharmas_NNP ,_,
        because_IN it_PRP would_MD help_VB to_TO contain_VB the_DT costs_NNS of_IN discovering_VBG ,_, developing_VBG ,_, and_CC manufacturing_NN
        drugs_NNS ._.
      
      
        Cost_NN Containment_NNP
        TDI_NNP would_MD contain_VB costs_NNS in_IN three_CD important_JJ ways_NNS ._. First_LS ,_, TDI_NNP would_MD ask_VB volunteers_NNS to_TO
        donate_VB their_PRP$ time_NN (_( and_CC any_DT patentable_JJ discoveries_NNS )_) to_TO the_DT collaboration_NN ._. Instead_RB of_IN
        financial_JJ incentives_NNS ,_, TDI_NNP would_MD offer_VB volunteers_NNS non-monetary_JJ rewards_NNS ,_, such_JJ as_IN ideological_JJ
        satisfaction_NN ,_, the_DT acquisition_NN of_IN new_JJ skills_NNS ,_, enhancement_NN of_IN professional_JJ reputation_NN ,_, and_CC
        the_DT ability_NN to_TO advertise_VB one_CD 's_POS skills_NNS to_TO potential_JJ employers_NNS ._. Software_NNP collaborations_NNS have_VBP
        demonstrated_VBN that_IN these_DT incentives_NNS are_VBP a_DT good_JJ way_NN to_TO attract_VB and_CC motivate_VB programmers_NNS [_NN 11_CD ]_NN ._.
        Similar_JJ incentives_NNS should_MD work_VB equally_RB well_RB for_IN biologists_NNS ,_, chemists_NNS ,_, and_CC other_JJ
        scientists_NNS ._.
        Second_JJ ,_, we_PRP have_VBP already_RB pointed_VBN out_RP that_IN existing_VBG proposals_NNS have_VBP difficulty_NN containing_VBG
        costs_NNS ._. The_DT root_NN cause_NN is_VBZ patents_NNS ._. Normally_RB ,_, society_NN relies_VBZ on_IN competition_NN to_TO keep_VB prices_NNS
        low_JJ ._. Patents—by_NNP design—short-circuit_JJ competition_NN by_IN giving_VBG the_DT owners_NNS the_DT legal_JJ right_NN to_TO
        prevent_VB others_NNS from_IN using_VBG (_( or_CC even_RB developing_VBG )_) their_PRP$ invention_NN ._. TDI_NNP ,_, on_IN the_DT other_JJ hand_NN ,_,
        would_MD restore_VB competition_NN by_IN making_VBG drug_NN candidates_NNS available_JJ to_TO anyone_NN who_WP wanted_VBD to_TO
        develop_VB them_PRP ._. We_PRP expect_VBP sponsors_NNS to_TO exploit_VB this_DT advantage_NN by_IN signing_VBG development_NN contracts_NNS
        with_IN whichever_WDT company_NN offers_VBZ the_DT lowest_JJS bid_NN ._. Such_JJ competitive_JJ bidding_NN is_VBZ a_DT powerful_JJ way_NN to_TO
        contain_VB costs_NNS ,_, and_CC is_VBZ also_RB a_DT good_JJ way_NN to_TO develop_VB drugs_NNS ._. Virtual_NNP Pharma_NNP has_VBZ extensive_JJ
        experience_NN supervising_VBG contract_NN research_NN ._.
        Third_NNP ,_, the_DT absence_NN of_IN patents_NNS would_MD continue_VB to_TO keep_VB prices_NNS low_JJ once_RB drugs_NNS reached_VBD the_DT
        market_NN ._. The_DT generic_JJ drug_NN industry_NN shows_VBZ what_WP happens_VBZ once_RB drug_NN makers_NNS are_VBP allowed_VBN to_TO
        compete_VB ._. US_NNP drugs_NNS frequently_RB fall_VBP to_TO about_IN one-third_NN their_PRP$ original_JJ price_NN when_WRB patents_NNS
        expire_VBP [_NN 12_CD ]_NN ._.
      
      
        Intellectual_NNP Property_NNP Rights_NNP
        Would_MD universities_NNS and_CC corporations_NNS really_RB let_VBP their_PRP$ people_NNS volunteer_NN ?_. Wo_NNP n't_RB they_PRP insist_VB
        on_IN intellectual_JJ property_NN rights_NNS ?_. The_DT practical_JJ answer_NN is_VBZ that_IN sensible_JJ managers_NNS do_VBP not_RB care_VB
        about_IN intellectual_JJ property_NN rights_NNS unless_IN they_PRP expect_VBP to_TO earn_VB a_DT profit_NN ._. This_DT explains_VBZ why_WRB
        sophisticated_JJ university_NN licensing_NN offices_NNS seldom_RB bother_VBP to_TO interfere_VB with_IN open-source_JJ
        software_NN projects_NNS that_WDT are_VBP not_RB commercially_RB valuable_JJ [_NN 13_CD ]_NN ._. The_DT same_JJ logic_NN would_MD apply_VB to_TO
        open-source_JJ drug_NN discovery_NN ._. We_PRP would_MD hope_VB that_IN life_NN sciences_NNS companies_NNS would_MD make_VB a_DT similar_JJ
        calculation_NN ._. But_CC permitting_VBG employees_NNS to_TO participate_VB is_VBZ only_RB the_DT beginning_NN ._. We_PRP think_VBP that_IN
        universities_NNS and_CC companies_NNS will_MD also_RB donate_VB the_DT data_NNS ,_, research_NN tools_NNS ,_, and_CC other_JJ resources_NNS
        needed_VBN to_TO make_VB TDI_NNP even_RB stronger_JJR ._. The_DT reason_NN ,_, once_RB again_RB ,_, is_VBZ that_IN they_PRP have_VBP little_JJ to_TO lose_VB ._.
        The_DT value_NN of_IN their_PRP$ intellectual_JJ property_NN depends_VBZ almost_RB entirely_RB on_IN US_NNP and_CC European_JJ
        diseases_NNS ._. For_IN this_DT reason_NN ,_, it_PRP costs_VBZ very_RB little_JJ to_TO share_VB their_PRP$ information_NN with_IN tropical_JJ
        disease_NN researchers_NNS ._. In_IN fact_NN ,_, drug_NN companies_NNS already_RB do_VBP this_DT [_NN 14_CD ]_NN ._. TDI_NNP 's_POS main_JJ challenge_NN
        will_MD be_VB to_TO show_VB donors_NNS that_IN an_DT open-source_JJ project_NN can_MD keep_VB members_NNS from_IN diverting_VBG donated_VBN
        information_NN back_RB into_IN the_DT commercially_RB lucrative_JJ diseases_NNS that_WDT affect_VBP patients_NNS in_IN the_DT
        West_NNP ._.
        Finally_RB ,_, there_EX are_VBP precedents_NNS for_IN private_JJ companies_NNS developing_VBG drugs_NNS off_IN patent_NN ._. During_IN
        the_DT 1950_CD s_VBZ ,_, March_NNP of_IN Dimes_NNP (_( see_VB www_NN ._. marchofdimes_NNS ._. com_NN )_) developed_VBN polio_NN vaccines_NNS without_IN any_DT
        patents_NNS at_IN all_DT [_NN 15_CD ]_NN ._. It_PRP then_RB signed_VBD guaranteed_VBN purchase_NN contracts_NNS with_IN any_DT drug_NN maker_NN
        willing_JJ to_TO develop_VB commercial-scale_JJ production_NN methods_NNS ._. The_DT incentive_NN may_MD not_RB have_VB been_VBN
        conventional_JJ ,_, but_CC it_PRP worked_VBD ._. And_CC why_WRB not_RB ?_. The_DT contracts_NNS made_VBD good_JJ business_NN sense_NN :_: contract_NN
        profits_NNS may_MD have_VB been_VBN small_JJ compared_VBN to_TO the_DT profits_NNS on_IN patented_VBD drugs_NNS ,_, but_CC so_RB was_VBD the_DT risk_NN ._.
        Fifty_NNP years_NNS later_RB ,_, contract_NN research_NN still_RB makes_VBZ sense_NN ._. Generic_NNP drug_NN companies_NNS ,_, developing_VBG
        world_NN drug_NN manufacturers_NNS ,_, contract_NN research_NN organizations_NNS ,_, and_CC biotech_JJ firms_NNS have_VBP all_DT said_VBN
        that_IN they_PRP would_MD consider_VB contracts_NNS to_TO develop_VB open-source_JJ drug_NN candidates_NNS ._. (_( M_NNP ._. Spino_NNP ,_, S_NNP ._.
        Sharma_NNP ,_, F_NN ._. Hijek_NNP ,_, and_CC D_NNP ._. Francis_NNP ,_, personal_JJ communications_NNS )_) ._.
      
      
        Next_JJ Steps_NNS
        So_RB far_RB ,_, we_PRP have_VBP described_VBN a_DT shoestring_NN operation_NN that_WDT exists_VBZ mainly_RB on_IN the_DT Web_NNP ._. Except_IN
        for_IN computer_NN time_NN ,_, budgets_NNS would_MD be_VB more_JJR or_CC less_JJR the_DT same_JJ as_IN existing_VBG software_NN
        collaborations_NNS ._. Computing_NNP would_MD be_VB expensive_JJ but_CC manageable_JJ ._. Today_NN 's_POS biologists_NNS routinely_RB
        scrounge_VBP resources_NNS from_IN university_NN machines_NNS or_CC borrow_VB time_NN on_IN home_NN computers_NNS [_NN 16_CD ,_, 17_CD ]_NN ._. This_DT
        Web-centric_NNP approach_NN would_MD be_VB a_DT good_JJ start_NN ,_, but_CC not_RB a_DT complete_JJ solution_NN ._. Computational_NNP
        biology_NN works_VBZ best_JJS when_WRB it_PRP can_MD interact_NN with_IN experimental_JJ chemistry_NN and_CC biology_NN ._.
        Nevertheless_RB ,_, a_DT low-budget_JJ computational_NN approach_NN is_VBZ probably_RB enough_RB to_TO generate_VB new_JJ
        science_NN ,_, suggest_VBP ideas_NNS for_IN follow-up_JJ experiments_NNS ,_, and_CC make_VB new_JJ drug_NN candidates_NNS available_JJ
        under_IN licenses_NNS designed_VBN to_TO yield_VB maximum_NN benefit_NN to_TO the_DT developing_VBG world_NN ._.
        In_IN practice_NN ,_, an_DT open-source_JJ drug_NN discovery_NN effort_NN is_VBZ likely_JJ to_TO include_VB modest_JJ
        experiments_NNS ._. Many_JJ academic_JJ scientists_NNS control_VBP discretionary_JJ resources_NNS and_CC ,_, in_IN some_DT cases_NNS ,_,
        tropical_JJ disease_NN grants_NNS ._. Furthermore_RB ,_, good_JJ science_NN generates_VBZ its_PRP$ own_JJ funding_NN ._. We_PRP expect_VBP
        experimentalists_NNS to_TO turn_VB the_DT collaboration_NN 's_POS Web_NNP pages_NNS into_IN grant_NN proposals_NNS ._.
        That_DT said_VBD ,_, TDI_NNP 's_POS volunteers_NNS will_MD be_VB most_RBS productive_JJ if_IN sponsors_NNS back_RB them_PRP ._. Charities_NNS
        could_MD support_VB open-source_JJ drug_NN discovery_NN by_IN making_VBG wet_JJ chemistry_NN and_CC biology_NN experiments_NNS a_DT
        top_JJ priority_NN ._. Corporations_NNS could_MD also_RB help_VB by_IN donating_VBG funds_NNS ,_, laboratory_NN time_NN ,_, or_CC
        previously_RB unpublished_JJ results_NNS ._. One_CD low_JJ cost_NN /_NN high_JJ value_NN option_NN would_MD be_VB for_IN companies_NNS that_WDT
        have_VBP already_RB tried_VBN a_DT particular_JJ research_NN direction_NN to_TO warn_VB TDI_NNP if_IN the_DT collaboration_NN was_VBD
        about_IN to_TO investigate_VB a_DT known_VBN dead_JJ end_NN ._. (_( R_NN ._. Altman_NNP ,_, personal_JJ communication_NN )_)
      
      
        Conclusion_NNP
        Open-source_NNP drug_NN discovery_NN is_VBZ feasible—that_NN is_VBZ ,_, no_DT known_VBN scientific_JJ or_CC economic_JJ barrier_NN
        bars_VBZ the_DT way_NN ._. But_CC what_WP are_VBP the_DT risks_NNS ?_. Experience_NN with_IN software_NN collaborations_NNS highlights_VBZ
        the_DT main_JJ social_JJ and_CC economic_JJ challenges_NNS ._. First_LS ,_, the_DT project_NN will_MD have_VB to_TO find_VB and_CC motivate_VB
        volunteers_NNS ._. Based_VBN on_IN existing_VBG software_NN collaborations_NNS ,_, we_PRP estimate_VBP a_DT required_JJ minimum_JJ
        “ critical_JJ mass_NN” of_IN a_DT few_JJ dozen_NN active_JJ members_NNS ._. Second_JJ ,_, modest_JJ chemistry_NN and_CC biology_NN
        experiments_NNS will_MD be_VB needed_VBN to_TO increase_VB the_DT chances_NNS for_IN success_NN ._. Resources_NNPS of_IN several_JJ
        hundred_CD thousand_CD dollars_NNS per_IN year—mostly_RB in_IN the_DT form_NN of_IN in-kind_JJ donations_NNS of_IN databases_NNS ,_,
        laboratory_NN access_NN ,_, and_CC computing_NN time—would_NN make_NN open-source_JJ drug_NN discovery_NN much_RB more_RBR
        powerful_JJ ._. By_IN most_JJS standards_NNS ,_, such_JJ risks_NNS are_VBP real_JJ but_CC acceptable_JJ ._.
        The_DT largest_JJS uncertainties_NNS are_VBP scientific_JJ ._. Can_MD a_DT volunteer_VB effort_NN based_VBN on_IN computational_NN
        biology_NN and_CC modest_JJ experiments_NNS produce_VBP the_DT high-quality_JJ drug_NN candidates_NNS that_IN Virtual_NNP Pharma_NNP
        needs_VBZ ?_. A_DT successful_JJ program_NN must_MD (_( 1_LS )_) make_VB a_DT significant_JJ contribution_NN toward_IN supplying_VBG the_DT
        genomic_JJ insights_NNS that_IN tropical_JJ disease_NN research_NN needs_VBZ to_TO move_VB forward_RB ,_, and_CC (_( 2_LS )_) make_VB useful_JJ
        drug_NN candidates_NNS available_JJ for_IN development_NN and_CC production_NN under_IN open-source_JJ licenses_NNS ._.
        Open-source_NNP drug_NN discovery_NN looks_VBZ feasible_JJ ._. The_DT only_JJ way_NN to_TO be_VB sure_JJ is_VBZ to_TO do_VB the_DT
        experiment—and_NN we_PRP invite_VB you_PRP to_TO join_VB us_PRP ._.
        
          To_TO learn_VB more_JJR about_IN TDI_NNP or_CC to_TO volunteer_VB ,_, go_VB to_TO
          http_NN :_: /_NN /_NN www_NN ._. tropicaldisease_NN ._. org_NN
        
      
    
  
